STOCK TITAN

Zura Bio Ltd - ZURA STOCK NEWS

Welcome to our dedicated news page for Zura Bio (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zura Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zura Bio's position in the market.

Rhea-AI Summary
Zura Bio, a clinical stage immunology company, announced an oversubscribed $112.5 million private placement led by Access Biotechnology and other institutional investors. The financing is expected to fund operations through 2027, supporting the development of tibulizumab for autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Zura Bio appoints Robert Lisicki as CEO and Director, succeeding Dr. Someit Sidhu. The company aims to establish itself as a leading immunology company with a focus on developing novel dual-pathway antibodies for autoimmune and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
none
-
Rhea-AI Summary
Zura Bio (Nasdaq: ZURA) reported significant 2023 milestones, including a successful Nasdaq listing, a new CEO appointment, and a robust financial position. The company raised $145 million in 1H 2023, closed a Business Combination Agreement with JATT Acquisition Corp., and completed an $80 million financing round. Zura Bio's cash position as of December 31, 2023, stood at $99.8 million, supporting operations until 2026. The company plans to initiate a Phase 2 study for tibulizumab (ZB-106) in systemic sclerosis in 2H 2024, while also advancing ZB-168 and torudokimab towards Phase 2 readiness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.78%
Tags
management earnings
Rhea-AI Summary
Zura Bio Limited (Nasdaq: ZURA) announces participation in three upcoming conferences in March, showcasing key members of its management team. The conferences include Leerink Global Biopharma Conference, Eighth Systemic Sclerosis World Congress, and BIO-Europe Spring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
none
-
Rhea-AI Summary
Zura Bio Limited (Nasdaq: ZURA) announced the participation of its senior management team in several upcoming conferences in February. The events include Oppenheimer 2024 Winter CEO and Investor Summit, Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, Oppenheimer 34th Annual Healthcare Life Sciences Conference, and Piper Sandler TSLP Biology Day. The company's executives will be involved in investor meetings, company presentations, and virtual discussions, focusing on the development of novel medicines for immune and inflammatory disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.11%
Tags
none
-
Rhea-AI Summary
Zura Bio Limited (ZURA) appoints Robert Lisicki as President and COO, and Kiran Nistala as EVP Development and CMO, positioning the company for Phase 2 clinical trial readiness across multiple indications in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
management
Rhea-AI Summary
Zura Bio Limited (ZURA) to Present at 2024 Dermatology Summit and 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
conferences
-
Rhea-AI Summary
Zura Bio Limited (ZURA) announced the acceptance and presentation of two abstracts at the World Allergy Congress, highlighting their research for ZB-168 and ZB-880, potential monoclonal antibodies for immune and inflammatory disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
none
-
Rhea-AI Summary
Zura Bio Limited (Nasdaq: ZURA) announces the appointment of Arnout Ploos van Amstel as Non-Executive Independent Director. Mr. Ploos van Amstel, with a successful track record in the global biotech and pharmaceutical sector, brings valuable expertise in strategy and business transformations to Zura Bio's Board. His extensive leadership experience and achievements in portfolio growth make him a significant asset for the company's sustained value creation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
management
Rhea-AI Summary
Zura Bio Limited (Nasdaq: ZURA) announced the initiation of Phase 2 clinical trials in 2024 for ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata. The company has a cash position of $103.9 million expected to support development and operations into 2026. Third Quarter 2023 Business Highlights include significant progress in strategic planning across Clinical, Regulatory, CMC, and Translational Science, positioning Zura Bio for clinical trial readiness in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.54%
Tags
Zura Bio Ltd

Nasdaq:ZURA

ZURA Rankings

ZURA Stock Data

146.47M
7.81M
59.43%
45.92%
1.44%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Cayman Islands
Po Box 309 Ugland House

About ZURA

zura bio is a clinical-stage biotechnology company advancing zb-168 in alopecia areata and other inflammatory diseases. zb-168 is an anti il7rα inhibitor that has the potential to impact diseases driven by il7 and tslp biological pathways. zura bio aims to develop a portfolio of therapeutic indications for zb-168, and is focused on demonstrating its efficacy, safety, dosing convenience and mechanism of action, initially in alopecia areata. this will build on phase 1b data in type 1 diabetes demonstrating a favourable safety profile and strong biological rationale. zura bio is headquartered in london, uk with team members in the uk and usa.